Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test may spot hidden cancer cells after surgery

NCT ID NCT04726800

Knowledge-focused Sponsor: Anna Martling Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 21, 2026 · Last updated Aug 21, 2026

Summary

This pilot study is testing whether a simple blood test can detect tiny amounts of tumor DNA (ctDNA) in patients with early-stage colorectal cancer before and after surgery. The goal is to see if this test is practical and reliable for spotting any cancer cells left behind, which could help guide future treatment decisions. If it works, it may lead to a larger study where patients with positive ctDNA receive additional therapy to prevent relapse.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
circulating tumor DNA (ctDNA) blood test
What this could lead to
If successful, this could lead to a larger study where patients with positive ctDNA after surgery receive extra treatment to reduce relapse risk.
What could go wrong
This is a small pilot study focused on feasibility, not treatment outcomes. The test may not reliably predict relapse, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 300 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2020

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The pilot study will include patients diagnosed with colorectal cancer stage I-III invited to participate in the ALASCCA study.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Colon or rectal cancer tumor stage I-III planned for radical surgery * Clean Colonoscopy or Computed Tomography (CT) colon within 3 months preoperatively or postoperatively but before randomization * Patient able to understand and sign written informed consent Exclusion Criteria: * Distant metastases * Other cancers (excluding colorectal cancer or other skin cancer than melanoma) within 3 years from screening * Significant medical illness that would interfere with study participation * Pregnancy or breastfeeding females * Current participation in another clinical trial that will be in conflict with the present study * Patients who are unlikely to comply with the protocol (e.g. uncooperative attitude, inability to return for subsequent visits) and/or otherwise considered by the Investigator to be unlikely to complete the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Colorectal cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

colonic neoplasm colorectal cancer colorectal neoplasm rectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Colorectal cancer

Contacts and locations

Locations

  • Akershus Univeristy Hospital

    Oslo, Norway

  • Capio Sankt Göran Hospital

    Stockholm, Sweden

  • Danderyd University Hospital

    Stockholm, Sweden

  • Ersta Hospital

    Stockholm, Sweden

  • Karolinska University Hospital

    Stockholm, Sweden

  • Sahlgrenska University Hospital

    Gothenburg, Sweden

  • Skaraborg Hospital

    Skövde, Sweden

  • South Hospital

    Stockholm, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.